Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,299 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06926075RecruitingPhase 1/Phase 2
Early trial of KESONOTIDE™ for solid tumors
This trial tests a new tablet called KESONOTIDE™ for people with solid tumors that have spread. The goal is to see if it can help when other treatments have stopped working or are not an option.
Kogarah, New South WalesAges 18 years+ - NCT06922591RecruitingPhase 1/Phase 2
TNG462 for pancreatic and lung cancer with MTAP loss
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06487780Recruiting
Preventing foot ulcers with a lifestyle program
This trial tests whether a lifestyle program can help people with diabetes avoid new foot ulcers. If you've healed from a foot ulcer in the last year, you may be able to join.
Downey, CaliforniaAges 21 years+ - NCT06921837RecruitingPhase 1/Phase 2
BDC-4182 for advanced gastric or gastroesophageal cancer
This trial tests a new drug called BDC-4182 for advanced gastric or gastroesophageal cancer. It is for people who have already tried standard treatments and may target a protein called Claudin 18 on some cancer cells.
Darlinghurst, New South WalesAges 18 years+ - NCT06917573RecruitingPhase 2
Cemiplimab for advanced lung cancer with high PD-L1
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
Alicante, AlicanteAges 18 years+ - NCT05283044Recruiting
Precision medicine testing for advanced, hard-to-remove cancers
This study helps doctors use more individualized (precision) treatment choices for people with certain advanced cancers. You may be offered study care based on your cancer details, aiming to improve treatment decisions.
BayonneAges 18 years+ - NCT05692999RecruitingPhase 3
Maintenance pembrolizumab dose study for non-squamous lung cancer
This Phase 3 trial tests two maintenance schedules (“usual” dose versus a lower dose) of pembrolizumab after your initial chemotherapy with pembrolizumab. It aims to see if the lower dose works well enough to control cancer while possibly reducing side effects.
NamurAges 18 years+ - NCT06665178RecruitingPhase 2
Testing SG after T-DXd in ER+/HER2-low metastatic breast cancer
This trial tests whether a different chemotherapy drug, called sacituzumab govitecan (SG), can help people with ER+/HER2-low metastatic breast cancer who have already been treated with trastuzumab deruxtecan (T-DXd). It also looks at genetic markers in your tumor to predict who might benefit from SG.
Vancouver, British ColumbiaAges 18 years+ - NCT06902792Enrolling by invitationPhase 1
Adebrelimab and trametinib for children with hard-to-treat LCH
This trial tests a combination of two drugs for children and teens with Langerhans cell histiocytosis (LCH) that has not responded to standard treatments or has come back after treatment. The goal is to see if the drugs can shrink lesions and improve symptoms.
Wenzhou, ZhejiangAges Up to 18 years - NCT06902272RecruitingPhase 2
Blood test to predict chemo-immunotherapy response in lung cancer
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
Miami, FloridaAges 18 years+ - NCT06905054RecruitingPhase 2
Preventing PSC recurrence after liver transplant
This trial tests whether fenofibrate can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. It is for adults who had a liver transplant for PSC between 1 and 7 years ago and have certain risk factors.
Scottsdale, ArizonaAges 18–75 - NCT04765098RecruitingPhase 2
Tamoxifen or Etoposide for recurring brain tumor after prior treatment
This trial tests whether tamoxifen works as well as etoposide in people whose glioblastoma has come back after standard chemotherapy and radiation with temozolomide. It aims to find a better medication option for controlling the tumor after the first return.
Edmonton, AlbertaAges 18–65 - NCT06893380Recruiting
Drug combo plus immunotherapy for advanced bile duct cancer
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06896110Enrolling by invitationPhase 1
Spinal chemo and immunotherapy for recurrent high-grade glioma
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
Iowa City, IowaAges 13 years+ - NCT05933733Recruiting
Salvage treatment for breast cancer that returned locally
This trial looks at how well “salvage” treatments work for breast cancer that has come back only in the local area (like the chest wall or nearby lymph nodes), without spreading to distant organs. It also tracks side effects to better understand the risks and benefits for patients who need additional treatment.
SeoulAges 18–100 - NCT06879860Enrolling by invitation
Comparing stitch vs no stitch for groin hernia repair
This study compares two ways to fix a mesh during groin hernia surgery: 3D patch with one stitch versus no stitches at all. It aims to see which method leads to less long-term pain and fewer hernias coming back. If you have a first-time, moderately large groin hernia, you may qualify.
Nanchong, SichuanAges 18–80 - NCT06883136Enrolling by invitation
Sintilimab plus chemo for elderly advanced lung cancer
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
Jinan, ShandongAges 60–80 - NCT06886516RecruitingEarly Phase 1
Blood thinner study for cancer patients with low platelets
This study tests if the blood thinner apixaban is safe and effective for cancer patients who have low platelets and a recent blood clot. It may offer a treatment option for those who cannot take standard blood thinners.
Boston, MassachusettsAges 18 years+ - NCT06883747RecruitingEarly Phase 1
Study of BMS-986504 for recurrent brain tumor
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
Phoenix, ArizonaAges 18 years+ - NCT06882486Recruiting
Kidney removal after successful immunotherapy for metastatic cancer
This trial is for people with kidney cancer that has spread to other parts of the body, who still have their original kidney tumor. If your cancer has responded very well to immunotherapy (a type of treatment that helps your immune system fight cancer), doctors want to see if removing the kidney tumor now can improve your outcome.
Marseille, Institut Paoli-calmettesAges 18 years+ - NCT06883396Recruiting
Looking at why MPFL knee surgery fails
This study looks at why some people's kneecaps keep dislocating after a specific type of surgery (MPFL reconstruction). It aims to find risk factors that might cause the surgery to not work as well.
Redwood City, CaliforniaAges 10–35 - NCT05310643RecruitingPhase 2
Nivolumab and ipilimumab for bowel cancer resistant to anti-PD1
This Phase 2 study tests two immunotherapy medicines (nivolumab and ipilimumab) in people with metastatic colorectal cancer that has not responded to anti-PD1 treatment. It focuses on tumors with mismatch repair problems (dMMR) and/or high microsatellite instability (MSI).
BesançonAges 18 years+ - NCT06871410RecruitingPhase 1
Engineered immune cells for relapsed or refractory AML
This trial tests a new type of cell therapy called CD83 CAR T cells for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. These cells are designed to find and attack the leukemia cells while sparing healthy cells.
Buffalo, New YorkAges 18 years+ - NCT06865664RecruitingPhase 1
Engineered immune cells for relapsed rhabdomyosarcoma in youth
This early-phase trial tests a new immune cell therapy (CAR T cells) for children and young adults whose rhabdomyosarcoma has returned or not responded to standard treatments. The goal is to see if these specially engineered cells can find and attack the cancer.
Bethesda, MarylandAges 3–39
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,299 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.